Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

NCT01404169 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT01404169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01404169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
Lead sponsor
Eisai Limited
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
September 30, 2014
Enrollment
260 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's type dementia